OPA1 and breast carcinoma: We further tested whether MYLS22, the first in class safe and specific Opa1 inhibitor discovered by Stéphanie Herkenne et al. (Zamberlan et al., 2022), and Oligomycin A, a mitochondrial F0F1-ATPase inhibitor, could recapitulate the effects of genetic OPA1 silencing on breast cancer cell phenotype.